IP Library Granted Patent US 10,406,394
Granted Patent B2
US 10,406,394 · App. 14/828,005 · Granted Sep 10, 2019

Abuse potential reduction in abusable substance dosage form

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,406,394
App. No.
14/828,005
Granted
Sep 10, 2019
Kind
B2
Abstract

The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Claims (31)

1. A system for reducing potential for abuse of a substance, the system comprising:

(a) the substance; and

(b) a container comprising an anti-abuse layer attached to a side of the container.

2. The system according to claim 1 , wherein the anti-abuse layer comprises an absorbent material.

3. The system according to claim 2 , wherein the absorbent material comprises activated carbon.

4. The system according to claim 1 , wherein the container comprises a pouch.

5. The system according to claim 1 , wherein the container comprises a closure system configured to seal the container.

6. The system according to claim 5 , wherein the closure system comprises an adhesive.

7. The system according to claim 5 , wherein the closure system comprises a ziplock.

8. The system according to claim 1 , wherein the substance is an opioid.

9. The system according to claim 8 , herein the opioid is fentanyl.

10. The system according to claim 1 , wherein the anti-abuse layer comprises an anti-abuse substance selected from the group consisting of co-soluble antagonists, irritants and combinations thereof.

11. The system according to claim 10 , wherein the anti-abuse substance includes an amount of an antagonist.

12. The system according to claim 10 , wherein the anti-abuse substance includes an amount of an irritant.

13. A system for reducing potential for abuse of a substance, the system comprising:

(a) the substance; and

(b) a pouch comprising:

(i) an anti-abuse layer comprising an absorbent material attached to a side of the pouch; and

(ii) a closure system at an opening of the pouch.

14. The system according to claim 13 , wherein the absorbent material comprises activated carbon.

15. The system according to claim 13 , wherein the closure system comprises an adhesive.

16. The system according to claim 13 , wherein the substance is an opioid.

17. The system according to claim 16 , wherein the opioid is fentanyl.

18. The system according to claim 13 , wherein the anti-abuse layer further comprises an anti-abuse substance selected from the group consisting of co-soluble antagonists, irritants and combinations thereof.

19. The system according to claim 18 , wherein the anti-abuse substance includes an amount of an antagonist.

20. The system according to claim 18 , wherein the anti-abuse substance includes an amount of an irritant.

21. A system for reducing potential for abuse of a fentanyl composition, the system comprising:

(a) a fentanyl composition; and

(b) a pouch comprising:

(i) an anti-abuse layer comprising activated carbon attached to a side of the pouch; and

(ii) a closure system comprising an adhesive at an opening of the pouch.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 29, 2016
From: TEIKOKU PHARMA USA, INC.
To: VERDE ENVIRONMENTAL TECHNOLOGIES, INC.
Reel/Frame 039563/0875 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: ANDERSON, CARTER R.; MORRIS, RUSSELL L.
To: BIRCH POINT MEDICAL, INC.
Reel/Frame 036351/0744 →
MERGER AND CHANGE OF NAME Recorded Aug 18, 2015
From: BIRCH POINT MEDICAL, INC.; TRAVANTI PHARMA INC.
To: TRAVANTI PHARMA INC.
Reel/Frame 036351/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: TRAVANTI PHARMA INC.
To: TEIKOKU PHARMA USA, INC.
Reel/Frame 036351/0776 →